Treace Medical Concepts (NASDAQ: TMCI) Exceeds Q3 2026 Estimates Despite Continued Unprofitability

Font: Financial Modeling Prep  • Nov 06, 2026

• Treace Medical Concepts (NASDAQ: TMCI) reported an adjusted Q3 2026 loss of $0.19 per share, outperforming the estimated loss of $0.25 per share.
• Revenue reached $48.25 million, surpassing the $47.8 million estimate, though it marked a decrease from the prior year's $50.21 million.
• Despite improved financial metrics, including a narrower net loss and positive Adjusted EBITDA, the company remains unprofitable, as indicated by its negative price-to-earnings and enterprise-value-to-operating-cash-flow ratios.

Treace Medical Concepts (NASDAQ: TMCI) makes devices used in bunion surgery, including its Lapiplasty procedure. It reports an adjusted third-quarter 2026 loss of $0.19 per share, better than the estimated loss of $0.25 per share. Adjusted earnings per share exclude certain costs to show how the underlying business performs.

Revenue reaches $48.3 million, above the $47.8 million estimate. The more precise reported figure is $48.25 million, down from $50.21 million a year earlier. As highlighted by Zacks, TMCI beats earnings estimates for the fourth straight quarter and revenue estimates in three of the past four quarters.

The smaller per-share loss comes alongside a narrower total net loss. As highlighted by GlobeNewswire, TMCI’s net loss falls 23% from a year earlier to $12.6 million. Adjusted EBITDA, a measure of earnings before interest, taxes and certain other costs, improves by $2.9 million to $0.3 million.

TMCI says its year-to-date cash usage falls 53%, or $9.7 million, compared with the same period in 2025. It holds $39.8 million in cash, cash equivalents and marketable securities as of September 30. Its current ratio of 2.58 means current assets are 2.58 times current liabilities.

Despite the earnings beat, TMCI remains unprofitable. Its trailing price-to-earnings ratio is -4.69, reflecting negative earnings, and its enterprise-value-to-operating-cash-flow ratio is -30.55, reflecting negative operating cash flow. TMCI also reports five-year study results that it says show lasting positive outcomes for Lapiplasty.